We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+14.95%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.78B
AUM Growth
-$802M
Cap. Flow
-$1.61B
Cap. Flow %
-18.35%
Top 10 Hldgs %
33.27%
Holding
157
New
20
Increased
27
Reduced
40
Closed
17

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$131M
2
MRK icon
Merck
MRK
+$97.5M
3
EW icon
Edwards Lifesciences
EW
+$97.4M
4
AGN.PRA
Allergan plc
AGN.PRA
+$76.2M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$72.9M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$213M
2
BMY icon
Bristol-Myers Squibb
BMY
+$184M
3
ABBV icon
AbbVie
ABBV
+$152M
4
BSX icon
Boston Scientific
BSX
+$141M
5
AGN
Allergan plc
AGN
+$138M

Sector Composition

Rank Sector Weight
1 Healthcare 92.67%
2 Financials 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
51
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$53.8M 0.61%
1,166,200
-981,900
-46% -$55.4M
NTLA icon
52
Intellia Therapeutics
NTLA
$1.54B
$45.3M 0.52%
2,662,180
– –
LOXO
53
DELISTED
Loxo Oncology, Inc
LOXO
$45.2M 0.52%
1,728,000
-447,857
-21% -$11.7M
THC icon
54
Tenet Healthcare
THC
$22.2B
$45.2M 0.51%
1,993,000
+1,077,700
+118% +$28.1M
COO icon
55
Cooper Companies
COO
$14.1B
$44.8M 0.51%
1,000,400
-1,704,800
-63% -$77.6M
ASND icon
56
Ascendis Pharma A/S
ASND
$16.7B
$44M 0.5%
2,191,000
– –
DMTX
57
DELISTED
Dimension Therapeutics, Inc
DMTX
$43.1M 0.49%
5,397,698
– –
CI icon
58
Cigna
CI
$78.4B
$42.4M 0.48%
325,700
-3,900
-1% -$509K
VRAY
59
DELISTED
ViewRay, Inc.
VRAY
$41.3M 0.47%
9,127,990
+1,138,074
+14% +$4.34M
MGLN
60
DELISTED
Magellan Health Services, Inc.
MGLN
$37.6M 0.43%
699,700
-390,900
-36% -$23.6M
OTIC
61
DELISTED
Otonomy, Inc.
OTIC
$33.7M 0.38%
1,850,094
– –
SGYP
62
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$32.9M 0.38%
5,976,648
– –
AERI
63
DELISTED
Aerie Pharmaceuticals
AERI
$30.1M 0.34%
+797,100
New +$17.6M
JAZZ icon
64
Jazz Pharmaceuticals
JAZZ
$16.1B
$30M 0.34%
246,900
+156,900
+174% +$21.1M
LKFT
65
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$29.6M 0.34%
457,900
+105,200
+30% +$5.93M
LUMO
66
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$29.1M 0.33%
215,367
+39,644
+23% +$3.94M
IOVA icon
67
Iovance Biotherapeutics
IOVA
$2.09B
$27.8M 0.32%
3,382,900
– –
RNAC icon
68
Cartesian Therapeutics
RNAC
$217M
$26.3M 0.3%
61,427
– –
SYK icon
69
Stryker
SYK
$134B
$24.7M 0.28%
212,000
– –
MRK icon
70
CALL
Merck
MRK
$323B
$21.8M 0.25%
+366,800
New +$21.4M
EXAS
71
DELISTED
Exact Sciences
EXAS
$20.5M 0.23%
1,101,600
-1,029,600
-48% -$18.1M
EHTH icon
72
eHealth
EHTH
$42.2M
$20.3M 0.23%
1,815,000
+515,000
+40% +$6.06M
CYNA
73
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$20.1M 0.23%
499,999
-640,326
-56% -$15.8M
LLY icon
74
CALL
Eli Lilly
LLY
$1.08T
$20.1M 0.23%
+250,000
New +$20M
ABT icon
75
Abbott
ABT
$189B
$18.6M 0.21%
440,500
+203,500
+86% +$8.72M
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2016 Portfolio in Review

As of Q3 2016, OrbiMed held 157 positions worth $8.78B, down 8.4% from $9.58B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed withdrew a net $1.61B in Q3 2016, closing 17 positions and reducing 40 holdings. Its most notable exit was RELYPSA INC COM, an estimated $137M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Allergan plc worth $72.5M.

  • OrbiMed's largest Q3 2016 buy was Allergan plc: 88,200 shares worth $72.5M.
  • OrbiMed added most to Shire pic in Q3 2016, an estimated $131M increase.
  • OrbiMed's biggest Q3 2016 reduction was HCA Healthcare, cutting an estimated $213M.
  • OrbiMed fully exited RELYPSA INC COM in Q3 2016, selling an estimated $137M.
  • OrbiMed's ten largest holdings make up 33% of its $8.78B portfolio in Q3 2016.
  • OrbiMed opened 20 new positions and closed 17 in Q3 2016.
  • OrbiMed's portfolio value fell 8.4% quarter-over-quarter to $8.78B.

Based on OrbiMed's 13F filing for Q3 2016, filed 14 Nov 2016.